Immunology
Rotavirus vaccine
Brand: Rotarix®
PBAC's latest decision on Rotavirus vaccine: Not recommended (2006). Considered for prevention of rotavirus gastroenteritis in infants and children.
PBAC outcome
Not recommended
2006
ICER (AUD/QALY)
$45k/QALY
Range: $15k/QALY–$45k/QALY
Submissions
1
2006 → 2006
Eligible population infants and children
Therapy area Immunology Evidence base RCT Key trials Rota-023, Rota-036, Rota-004, Rota-005, Rota-006, Rota-007 Comparator placebo (standard medical management) Economic model CUA, CEA, Cost-minimisation Why PBAC said no
Reasons cited in the latest PSD: uncertain cost-effectiveness at the price requested, framing bias in disutility elicitation for QALY calculation, uncertainty about willingness-to-pay valuation methodology, administration costs not included in economic model, insufficient information on cost-effectiveness in restricted Aboriginal and Torres Strait Islander population
Open on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.